Nurse-Led Treat-to-Target Clinics
New studies shared at the 2025 annual EULAR congress in Barcelona highlight the benefits that nurse-led care can bring for both patients and healthcare systems.
Read Article
Safety of Recombinant Zoster Vaccine in Rheumatic Patients
New work presented at EULAR focuses on the RZV, which contains recombinant glycoprotein E – the major target of CD4+T-cells. The abstract describes the tolerability and safety of RZV in patients with inflammatory https://t.co/NS3h9CdGIU
Dr. John Cush @RheumNow( View Tweet )
Cancer risk in rheumatoid arthritis: anything new?
There is still a question I have a hard time answering with certainty when people living with rheumatoid arthritis ask me: Is there a higher risk of cancer that comes with the disease? Or with the treatments? So many https://t.co/6rbZg5Fr2k
Dr. John Cush @RheumNow( View Tweet )
How to properly use steroids in early RA
Guidelines differ on the early treatment of RA – ACR suggests not to use glucocorticoids (GC) and EULAR updated recommendations for RA treatment presented at #EULAR2025 continued to suggest early treatment with MTX and glucocorticoids. We do know that it is not easy to get a significant minority
Read Article
Increased Risk of VTE in RA: Lessons Learned from 40 Years of Data
Dr. Mrinalini Dey reports on abstract OP0070, "Trends in Incidence and Predictors of Incident Venous Thromboembolism in Patients with Rheumatoid Arthritis: A Population-Based Retrospective Cohort Study", https://t.co/JykR4Mxb9L
Dr. John Cush @RheumNow( View Tweet )
Methotrexate and Leflunomide combination in RA/PsA: Is it safe?
I asked the EULAR twitter sphere how they feel about combination of methotrexate (MTX) and leflunomide (LEF). The opinions are differing so far, with 50% reporting prescribing this combination often while 50% are worried of side effects. Several abstracts presented this year are providing
Read Article
The Impact of Biologics on Methotrexate Adherence
Dr. Aurelie Najm reports on abstract POS0563, 'Methotrexate biochemical adherence significantly reduces in new starters of biologic/targeted DMARDs: Results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study https://t.co/t7DEsJW35v
Dr. John Cush @RheumNow( View Tweet )
2025 update of EULAR recommendations on lupus nephritis
At the 2025 EULAR congress in Barcelona, Prof Dimitrios Boumpas presented a summary of the updated EULAR recommendations on the management of lupus nephritis (LN). The most significant change in the treatment paradigm of LN is that the historic standard of care (SOC) (i.e.
Read Article
Pregnancy outcomes in autoinflammatory disease
To address this, a French multi-centre prospective pregnancy observational cohort was set up, to analyse disease activity, treatment, pregnancy outcomes, delivery, and neonatal health. The work – presented at the 2025 annual congress of EULAR – showcased findings from 97 women with an
Read Article
Secukinumab Use in Refractory Giant Cell Arteritis
In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger https://t.co/HkMT9QEMg8
Dr. John Cush @RheumNow( View Tweet )
Sometimes you hear:
“PMR dose steroids don’t really matter”
Errrrr…
(You wouldn’t accept this steroid exposure in any other disease. Never)
#EULAR2025 POS0139 @RheumNow https://t.co/o6w2RpaGBj
David Liew @drdavidliew( View Tweet )
Management of SLE:
-Treat early to prevent organ damage
-Taper GC to <5mg/d in the first 6m when feasible
-New therapies are promising but still unmet needs in LN, limited global access and lacking data in pregnancy.
#EULAR2025 @RheumNow https://t.co/UKK8sTYJD2
Links:
Adela Castro @AdelaCastro222( View Tweet )
-Difficult to treat RA is a heterogeneous concept
-Risk fx: younger onset, high disease activity,erosive disease, comorbidities, depression.
-Study in a Spanish cohort with D2T 2/2 inefficacy showed Rituximab, JAKis, and IL-6i had longer survival (hence better tx options).
-The https://t.co/ZCZcX9FRfb
Adela Castro @AdelaCastro222( View Tweet )
#EULAR2025 Abstr#OP0041 FcRn-inhibition is showing consistency in #Sjogren. Last year it was Nipocalimab. This proof-of-concept study showed efgartigimod met its primary endpoint, the CRESS response. No difference in ESSPRI. Phase 3 UNITY is underway @RheumNow https://t.co/jw1i4FqkIh
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
#EULAR2025 Abstr#OP0035 SGLT2-i and GLP-1 agonist are increasingly used to treat diabetes. Population based study in Canada showed no significant difference in risk of developing an autoimmune rheumatic disease with GLP-1-RA or SGLT2i relative to DPP4i treatment @RheumNow https://t.co/CvPcOqehtl
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
#EULAR2025 Abstr#OP0202 Phase 1/2 of Resel-cel, a 4-1BB-containing human CD19-CAR T cell (weight-based 1 x infusion) reported efficacy in 8 patients (#SLE and LN) at WK28. 2 x Grade 1 CRS & 1 x Grade 4 ICANS. 1 x HLH, not attributed to SLE flare. Need longterm data @RheumNow https://t.co/COCKlqw687
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
#EULAR2025 Based on the updated EULAR Guidelines on #lupus nephritis, should all patients receive early Combination therapies for remission induction? @RheumNow
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
#Enpatoran a #TLRi in Phase2 #SLE #RCT
-previous data + small #cutaneous #lupus study
various doses &PBO approx 25/group
Interesting data - seems to ⬇️#IFN
+ endpoints
👀 for more to come! Safe so far
#EULAR2025 @RheumNow @eular_org LateBreaking I https://t.co/OtgiasBerX
Links:
Janet Pope @Janetbirdope( View Tweet )
FMF #Recommendations
#Colchicine can be fatal
🔺️Beware of drug interactions
🔺️Mostly statins in adults
🔺️Macrolides in children
#EULAR2025
@RheumNow https://t.co/SYGLpAJXFu
Nelly ZIADE 🍀 @Nellziade( View Tweet )
@RheumNow When it comes to ORAL Surveillance and the 2025 EULAR recommendations, the same sensibility remains.
Appropriate caution based on the RCT, despite observational data, but we’ll see what is yet to come. Plenty to watch this space for
#EULAR2025 @RheumNow https://t.co/fIxHRGDFcK
Links:
David Liew @drdavidliew( View Tweet )
Deucravacitinib, the first oral TYK2 inhibitor, delivers in PsA:
✅ ACR20: 54% vs 34% (placebo)
✅ Skin, joints, fatigue, QoL
📉 Post hoc: less radiographic progression
No new safety signals at W16.
LB0001 @RheumNow #EULAR2025
Jiha Lee @JihaRheum( View Tweet )
from Rituximab to BiTES to CAR T, always looking for deeper B cell depletion
Safety data from CC312 CD19/CD3/CD28, a triple engager in refractory moderate-to-severe SLE
So far so good but how far do we need to go?
#EULAR2025 @RheumNow LB0007
Aurelie Najm @AurelieRheumo( View Tweet )
#EULAR2025 Abstr#LB0001 Phase 3 RCT of Deucravacitinib in psoriatic arthritis met endpoints (ACR20) over PBO at Week 16. Prespecified early radiographic was not significant but post-hoc (without imputed data) showed radiographic inhibition @RheumNow https://t.co/ORUBtUWH31
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
🫁 In autoimmune ILD patients from FIBRONEER-ILD (n=325), nerandomilast slowed FVC decline vs placebo and reduced risk of ILD progression events (HR 0.56 for 18 mg BID).
Acceptable safety profile & tolerability.
@RheumNow #EULAR2025 #LB0003 https://t.co/aWsfNOL76n
Mrinalini Dey @DrMiniDey( View Tweet )
🌳#WILLOW: TLR7/8 inhibition with enpatoran led to greater BICLA response, IFN signature reduction & skin improvement (CLASI-50/70) in active SLE vs placebo at 24wks. Most benefit seen in pts with high IFN-GS or GC use. Good tolerability.
@RheumNow #EULAR2025 #LB0004
Mrinalini Dey @DrMiniDey( View Tweet )
Recent Blogs
